TABLE 3.

Multivariable analysis on overall survival

Variable	Group	Overall survival (from diagnosis)
		HR (95% CI)	p value
Age at diagnosis, years	> 55	0.90 (0.74–1.11)	0.342
	≤ 55	–	–
Sex	Male	0.93 (0.78–1.12)	0.462
	Female	–	–
Charlson–Deyo score	1+	1.19 (0.97–1.47)	0.095
	0	–	–
Treatment	SP alone	–	–
	Metastasectomy	0.45 (0.34v0.61)	< 0.001
	Non-surgical adjuvant therapies	0.53 (0.43–0.64)	< 0.001
Facility type	Community or Network Cancer Program	–	–
	Comprehensive Community Cancer Program	0.85 (0.64–1.12)	0.256
	Academic or Research Program	0.78 (0.61–0.98)	0.032
Tumor size, cm	> 15	1.84 (1.35–2.52)	< 0.001
	> 10–15	1.41 (1.03–1.94)	0.032
	> 5–10	1.04 (0.76–1.43)	0.790
	0–5	–	–
Grade	Well-differentiated	0.52 (0.22–1.21)	0.130
	Moderately differentiated	1.20 (0.78–1.83)	0.402
	Poorly differentiated or undifferentiated	1.26 (0.97–1.63)	0.085
	Cell type not determined	–	–
Histology	Adipocytic	0.43 (0.30–0.62)	< 0.001
	Fibroblastic or myofibroblastic or fibrohistiocytic	0.68 (0.52–0.88)	0.004
	Smooth muscle	0.67 (0.49–0.91)	0.010
	Skeletal muscle	0.61 (0.34–1.07)	0.085
	Vascular	1.05 (0.64–1.72)	0.853
	Nerve sheath	0.98 (0.56–1.70)	0.943
	Uncertain differentiation	0.79 (0.61–1.02)	0.074
	Undifferentiated or unclassified sarcoma	–	–
Surgical margins	Positive	1.44 (1.18–1.75)	< 0.001
	Negative	–	–

Bold values indicate statistical significance (p < 0.05)

HR Hazard ratio, CI Confidence interval, SP Surgical management of the primary site